APREA THERAPEUTICS, INC. (APRE) News
Filter APRE News Items
APRE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
APRE News Highlights
- For APRE, its 30 day story count is now at 4.
- Over the past 22 days, the trend for APRE's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- The most mentioned tickers in articles about APRE are LI, DNA and UL.
Latest APRE News From Around the Web
Below are the latest news stories about APREA THERAPEUTICS INC that investors may wish to consider to help them evaluate APRE as an investment opportunity.
Aprea Therapeutics to Present at BIO International ConventionDOYLESTOWN, Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview at the BIO International Convention, being held in Boston, Massachusetts from June 5-8, 2023. “We look forward to presen |
Aprea Therapeutics GAAP EPS of -$1.34
|
Aprea Therapeutics Reports First Quarter 2023 Financial Results and Provides Update on Business OperationsDOYLESTOWN, Pa., May 15, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months ended March 31, 2023 and provided a business update. “We are excited about the strong start for 2023 as we focus on the execution of the pipeline development plan a |
Aprea Therapeutics Appoints Gabriela Gruia, M.D. to Board of DirectorsDOYLESTOWN, Pa., May 08, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced the appointment of Gabriela Gruia, M.D. to its Board of Directors, effective as of May 5, 2023. Dr. Gruia joins Aprea with over 25 years of clinical, regulatory and life science leadership experience. “ |
Bears are Losing Control Over Aprea Therapeutics, Inc. (APRE), Here's Why It's a 'Buy' NowAprea Therapeutics, Inc. (APRE) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term. |
All You Need to Know About Aprea Therapeutics, Inc. (APRE) Rating Upgrade to BuyAprea Therapeutics, Inc. (APRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
Aprea Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Update on Business OperationsDOYLESTOWN, Pa., March 30, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical stage biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today reported financial results for the three months and year ended December 31, 2022 and provided a business update. “2022 has been another transformational year for Aprea with progress on multiple fronts,” said Or |
Aprea Therapeutics Announces Presentation of Preclinical Data on Pipeline Programs at the AACR 2023 Annual MeetingDOYLESTOWN, Pa., March 16, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that an abstract on its preclinical programs, ATRN-119 and ATRN-W1051, has been selected for presentation as a poster at the American Association for Cancer Research (AACR) 2023 Annual Meeting, being held April 14-1 |
Aprea Therapeutics to Present at Oppenheimer’s 33rd Annual Healthcare ConferenceDOYLESTOWN, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that Oren Gilad, Ph.D., President and Chief Executive Officer, will present a corporate overview and host 1x1 meetings at the Oppenheimer 33rd Annual Healthcare Conference, being held online from March 14-16, 2023. |
Aprea Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementDOYLESTOWN, Pa., March 01, 2023 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a biopharmaceutical company focused on developing novel synthetic lethality-based cancer therapeutics targeting DNA damage response (DDR) pathways, today announced that it received formal notice from The Nasdaq Stock Market ("Nasdaq") stating that the Company has regained compliance with Nasdaq's minimum bid price for continued listing on the Nasdaq Global Select Market as set |